Proteomic Profiles and Novel Biomarkers in Juvenile Rheumatoid Arthritis

幼年类风湿关节炎的蛋白质组谱和新型生物标志物

基本信息

项目摘要

DESCRIPTION: (provided by applicant): Juvenile Rheumatoid Arthritis (JRA) comprises a heterogeneous group of childhood onset, chronic, autoimmune diseases with variable clinical presentations, outcomes and therapeutic responses. Little is available by way of laboratory testing to help the pediatric rheumatologist in the initial evaluation of patients although clinical evaluation has been a central and important method of establishing likely diagnoses and outcomes. The sequencing of the human genome and advances in molecular technologies has provided a framework to unravel disease processes. Gene expression analysis is one approach to achieving this end, but it is protein, rather than RNA, that directly mediates disease. Thus, protein expression is likely to provide a better indicator of pathophysiologic pathways than does RNA expression. The field of proteomics, or protein pattern analysis, is the characterization and quantitation of proteins in tissues and body fluids. Disease proteomics has emerged as a rapidly advancing discipline for delineating altered protein expression, identifying novel biomarkers for the diagnosis and early detection of disease, and the identification of new targets for therapeutics. In the first specific aim, we will use a combination of Surface Enhanced Laser Desorption/lonization time of flight mass spectrometry (SELDI-TOF-MS), Cliniprot, and 2-dimensional gel analysis for delineating differential protein expression in peripheral blood and joint fluids to differentiate disease states and between subtypes of JRA. The second specific aim then proposes to identify these differentially expressed proteins and correlate them with the disease state and subtype of JRA. The overall goal of the studies will be to comprehensively identify proteomic profiles and differentially expressed proteins which are likely to be involved in pathogenic pathways in JRA. It will likely lead to greater understanding of the mechanism of disease as well as potentially serve as diagnostic and prognostic indicators of disease. Furthermore, these studies may lead to the identification of novel biomarkers and targets of therapy in JRA.
产品说明:(申请人提供):幼年型风湿性关节炎(JRA)包括一组异质性的儿童期发病的慢性自身免疫性疾病,具有不同的临床表现,结果和治疗反应。虽然临床评估是确定可能的诊断和结果的中心和重要方法,但通过实验室检测来帮助儿科风湿病学家对患者进行初步评估的方法很少。人类基因组测序和分子技术的进步为揭示疾病过程提供了框架。基因表达分析是实现这一目标的一种方法,但直接介导疾病的是蛋白质,而不是RNA。因此,蛋白质表达可能比RNA表达提供更好的病理生理学途径的指标。蛋白质组学或蛋白质模式分析的领域是组织和体液中蛋白质的表征和定量。 疾病蛋白质组学已成为一门快速发展的学科,用于描绘改变的蛋白质表达,鉴定用于疾病诊断和早期检测的新生物标志物,以及鉴定用于治疗的新靶点。在第一个具体目标中,我们将使用表面增强激光解吸/电离飞行时间质谱(SELDI-TOF-MS)、Cliniprot和二维凝胶分析的组合来描绘外周血和关节液中的差异蛋白表达,以区分疾病状态和JRA亚型。第二个具体目标,然后提出,以确定这些差异表达的蛋白质,并将它们与疾病状态和亚型的JRA。 研究的总体目标是全面鉴定可能参与JRA致病途径的蛋白质组学谱和差异表达蛋白。它可能会导致更好地了解疾病的机制,并可能作为疾病的诊断和预后指标。此外,这些研究可能会导致新的生物标志物和治疗JRA的目标的识别。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARGALIT E ROSENKRANZ其他文献

MARGALIT E ROSENKRANZ的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARGALIT E ROSENKRANZ', 18)}}的其他基金

Proteomic Profiles and Novel Biomarkers in Juvenile Rheumatoid Arthritis
幼年类风湿关节炎的蛋白质组谱和新型生物标志物
  • 批准号:
    7451056
  • 财政年份:
    2006
  • 资助金额:
    $ 19.82万
  • 项目类别:
Proteomic Profiles and Novel Biomarkers in Juvenile Rheumatoid Arthritis
幼年类风湿关节炎的蛋白质组谱和新型生物标志物
  • 批准号:
    7943112
  • 财政年份:
    2006
  • 资助金额:
    $ 19.82万
  • 项目类别:
Proteomic Profiles and Novel Biomarkers in Juvenile Rheumatoid Arthritis
幼年类风湿关节炎的蛋白质组谱和新型生物标志物
  • 批准号:
    7288792
  • 财政年份:
    2006
  • 资助金额:
    $ 19.82万
  • 项目类别:
Proteomic Profiles and Novel Biomarkers in Juvenile Rheumatoid Arthritis
幼年类风湿关节炎的蛋白质组谱和新型生物标志物
  • 批准号:
    7085186
  • 财政年份:
    2006
  • 资助金额:
    $ 19.82万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 19.82万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 19.82万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 19.82万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 19.82万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 19.82万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 19.82万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 19.82万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 19.82万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 19.82万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 19.82万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了